已收录 273192 条政策
 政策提纲
  • 暂无提纲
Loxiglumide, L-364, 718 and L-365, 260 Prevent the Inhibition of Spontaneous Acetylcholine Release from the Frontal Cerebral Cortex of Freely Moving Rat Peripherally Administered with Cholecystokinin-8S
[摘要] References(14)Cited-By(1)We examined the effect of peripheral administration of cholecystokinin (CCK)-8S on spontaneous acetylcholine (ACh) release from the frontal cortex and its prevention by loxiglumide, L-364, 718 and L-365, 260 in freely moving rats using intracerebral microdialysis. Subcutaneously (s.c.) administered CCK-8S at 10 and 30 μg/kg significantly decreased the release of ACh. The inhibitory effect of 10 μg/kg (s.c.) CCK-8S was prevented by loxiglumide, a mixed type of CCK-A and -B-receptor antagonist, at 1 mg/kg (intraperitoneal) and 40 μg/rat (intracerebroventricular, i.c.v.); L-364, 718, a CCK-A-receptor antagonist, at 125 and 250 ng/rat (i.c.v.); and L-365, 260, a CCK-B-receptor antagonist at 250 ng/rat (i.c.v.). These results demonstrate that peripherally administered CCK-8S inhibits spontaneous ACh release from the frontal cortex through both central CCK-A (mainly) and -B receptors.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 药理学
[关键词] Cholecystokinin-8S;Loxiglumide;Spontaneous acetylcholine release (frontal cortex) [时效性] 
   浏览次数:12      统一登录查看全文      激活码登录查看全文